IRX4204 sensitizes multiple myeloma to ferroptosis and improves lenalidomide efficacy through the HMOX1-GPX4 axis.
Saved in:
| Title: | IRX4204 sensitizes multiple myeloma to ferroptosis and improves lenalidomide efficacy through the HMOX1-GPX4 axis. |
|---|---|
| Authors: | Wu J; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, 27710, USA., Yan Z; Department of Pathology, Duke University School of Medicine, Durham, NC, 27710, USA., Burcher K; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, 27710, USA., Han Z; Department of Pathology, Duke University School of Medicine, Durham, NC, 27710, USA., Nikiforov MA; Department of Pathology, Duke University School of Medicine, Durham, NC, 27710, USA.; Department of Biomedical Engineering, Pratt School of Engineering, Duke University, Durham, NC, 27708, USA., Vuligonda V; Io Therapeutics, Inc, Spring, TX, 77387, USA., Sanders M; Io Therapeutics, Inc, Spring, TX, 77387, USA., Kang Y; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, 27710, USA. yubin.kang@duke.edu. |
| Source: | Scientific reports [Sci Rep] 2026 Mar 17; Vol. 16 (1). Date of Electronic Publication: 2026 Mar 17. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
